Regeneron Presents Detailed Results From Phase 3 Pivotal Trial For REGEN-COV WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals, Inc. (REGN) announced Monday the presentation of detailed results from the Phase 3 pivotal trial showing REGEN-COV (casirivimab with imdevimab) significantly reduced the risk of hospitalization or death, shortened symptom duration and reduced viral load in non-hospitalized patients (outpatients) with COVID-19. These data were presented at the 2021 American Thoracic Society International Conference (ATS 2021) in the Breaking News: Clinical Trial Results in Pulmonary Medicine Scientific Symposium, which features late-breaking information on leading clinical trials in pulmonary and critical care medicine. The company noted that despite increasing vaccination rates, many continue to be diagnosed with COVID-19 who could benefit from REGEN-COV due to underlying conditions like asthma or COPD that put them at higher risk for severe disease.